Guidance for Industry Drug Interaction Studies — Study Design , Data Analysis , Implications for Dosing , and Labeling Recommendations

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.

[1]  Shiew-Mei Huang,et al.  Drug interactions evaluation: an integrated part of risk assessment of therapeutics. , 2010, Toxicology and applied pharmacology.

[2]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[3]  Masoud Jamei,et al.  Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.

[4]  M. Jamei,et al.  Misuse of the Well-Stirred Model of Hepatic Drug Clearance , 2007, Drug Metabolism and Disposition.

[5]  Y. Sugiyama,et al.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. , 1998, Pharmacological reviews.

[6]  Shiew-Mei Huang,et al.  Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study , 2009, Journal of clinical pharmacology.

[7]  Shiew-Mei Huang,et al.  Predicting Drug–Drug Interactions: An FDA Perspective , 2009, The AAPS Journal.

[8]  D. Surry,et al.  Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  Yuichi Sugiyama,et al.  Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.

[10]  K. Ohashi,et al.  Effect of the Treatment Period With Erythromycin on Cytochrome P450 3A Activity in Humans , 2007, Journal of clinical pharmacology.

[11]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[12]  Shiew-Mei Huang,et al.  Complex Drug Interactions: Significance and Evaluation , 2010 .

[13]  A. Rostami-Hodjegan,et al.  'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. , 2004, Drug discovery today. Technologies.

[14]  L Zhang,et al.  Therapeutic Protein–Drug Interactions and Implications for Drug Development , 2010, Clinical pharmacology and therapeutics.

[15]  Masoud Jamei,et al.  Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. , 2008, Current drug metabolism.

[16]  K. Morrissey,et al.  Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction , 2008, Drug Metabolism and Disposition.

[17]  Lei Zhang,et al.  Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. , 2009, Molecular pharmaceutics.

[18]  Shiew-Mei Huang,et al.  Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential‐toward a consensus , 2001 .

[19]  Chuang Lu,et al.  The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America , 2009, Drug Metabolism and Disposition.

[20]  Sharon L Ripp,et al.  Evaluation of models for predicting drug–drug interactions due to induction , 2010, Expert opinion on drug metabolism & toxicology.

[21]  Alex Phipps,et al.  Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.

[22]  Yuichi Sugiyama,et al.  Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? , 2002, AAPS PharmSci.

[23]  Olivier Fardel,et al.  Regulation of Drug Transporter Expression in Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor-α or Interleukin-6 , 2009, Drug Metabolism and Disposition.

[24]  G. Vladutiu,et al.  SLCO1B1 variants and statin-induced myopathy. , 2009, The New England journal of medicine.

[25]  M Jamei,et al.  Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. , 2009, Current drug metabolism.

[26]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.

[27]  R. Obach,et al.  Cytochrome P 450 3 A 4 mRNA Is a More Reliable Marker than CYP 3 A 4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes , 2010 .